ADRX
ADARx Pharmaceuticals, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Strong sell
-60/100
Last price
18.58
▼ 0.47 (2.47%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
19.05
Day high
19.57
Day low
18.01
Volume
1.03M
Market cap
$1.98B
P/E (TTM)
—
52W range
17.30 – 23.21
Trailing performance
Returnvs SPY
1W
-9.98%
-11.9%
1M
—
-1.2%
3M
—
-4.5%
6M
—
-18.2%
YTD
-3.98%
-18.2%
1Y
—
-16.4%
3Y
—
-82.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
10 more panels on ADRX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
44.52M
Total on file
Fundamentals
Market cap$1.98B
Enterprise value$1.92B
Revenue (TTM)$6.13M
Gross profit$-83.74M
EBITDA$-105.12M
Net income$-87.87M
EPS (TTM)$-1.16
Free cash flow—
Total cash$427.25M
Total debt$6.90M
Book value / share$-22.16
Shares outstanding106.80M
Float43.85M
Short % of float—
Dividend yield0.00%
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue312.95
EV / EBITDA-18.24
Gross margin0.00%
Operating margin-4006.84%
Profit margin0.00%
Return on equity—
Return on assets—
Debt / equity6.47
Current ratio12.98
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | YoY |
|---|---|---|---|
| Total revenue | $3.45M | $0 | — |
| Operating revenue | $3.45M | $0 | — |
| Research & development | $71.51M | $43.36M | +64.9% |
| Selling, general & admin | $20.30M | $14.88M | +36.5% |
| Total operating expense | $91.81M | $58.23M | +57.7% |
| Operating income | -$88.36M | -$58.23M | -51.7% |
| Net interest income | $13.64M | $11.39M | +19.7% |
| Pre-tax income | -$73.09M | -$46.36M | -57.7% |
| Net income | -$73.09M | -$46.36M | -57.7% |
| Net income to common | -$73.09M | -$46.36M | -57.7% |
| Basic EPS | -0.97 | -0.62 | -57.6% |
| Diluted EPS | -0.97 | -0.62 | -57.6% |
| EBIT | -$88.36M | -$58.23M | -51.7% |
| EBITDA | -$86.04M | -$56.73M | -51.7% |
| Basic shares | 75.35M | 75.31M | +0.0% |
| Diluted shares | 75.35M | 75.31M | +0.0% |
| Line item | 2025 | 2024 | YoY |
|---|---|---|---|
| Cash & equivalents | $66.52M | $14.03M | +374.0% |
| Cash & short-term investments | $480.00M | $219.48M | +118.7% |
| Total current assets | $493.38M | $225.67M | +118.6% |
| Property, plant & equipment | $12.07M | $7.13M | +69.4% |
| Total assets | $507.65M | $233.45M | +117.5% |
| Total current liabilities | $30.48M | $8.94M | +241.1% |
| Total debt | $7.74M | $4.33M | +78.8% |
| Total liabilities | $709.91M | $370.60M | +91.6% |
| Retained earnings | -$220.70M | -$147.61M | -49.5% |
| Shareholder equity | -$202.25M | -$137.15M | -47.5% |
| Working capital | $462.89M | $216.73M | +113.6% |
| Net tangible assets | -$202.25M | -$137.15M | -47.5% |
| Shares issued | 102.20M | 102.20M | 0.0% |
| Line item | 2025 | 2024 | YoY |
|---|---|---|---|
| Net income | -$73.09M | -$46.36M | -57.7% |
| Depreciation & amortisation | $2.33M | $1.50M | +54.9% |
| Stock-based compensation | $6.13M | $3.95M | +55.2% |
| Change in working capital | $329.81M | -$564.00K | +58,577.1% |
| Operating cash flow | $262.29M | -$48.56M | +640.1% |
| Capital expenditure | -$2.94M | -$455.00K | -545.1% |
| Investing cash flow | -$209.93M | $39.51M | -631.3% |
| Financing cash flow | $97.00K | $225.00K | -56.9% |
| Free cash flow | $259.35M | -$49.02M | +629.1% |
| End cash position | $66.52M | $14.03M | +374.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|
| Total revenue | $746.00K | $2.14M | $208.00K | $0 | -65.1% |
| Operating revenue | $746.00K | $2.14M | $208.00K | $0 | -65.1% |
| Research & development | $24.74M | $23.58M | $17.07M | $12.89M | +4.9% |
| Selling, general & admin | $5.90M | $5.62M | $4.26M | $5.00M | +5.1% |
| Total operating expense | $30.64M | $29.20M | $21.33M | $17.89M | +4.9% |
| Operating income | -$29.89M | -$27.06M | -$21.12M | -$17.89M | -10.5% |
| Net interest income | $3.78M | $3.98M | $2.48M | $2.27M | -5.1% |
| Pre-tax income | -$25.76M | -$22.67M | -$18.09M | -$15.55M | -13.6% |
| Net income | -$25.76M | -$22.67M | -$18.09M | -$15.55M | -13.6% |
| Net income to common | -$25.76M | -$22.67M | -$18.09M | -$15.55M | -13.6% |
| Basic EPS | — | -0.22 | — | -0.21 | — |
| Diluted EPS | — | -0.22 | — | -0.21 | — |
| EBIT | -$29.89M | -$27.06M | -$21.12M | -$17.89M | -10.5% |
| EBITDA | -$29.16M | -$26.34M | -$20.50M | -$17.37M | -10.7% |
| Basic shares | — | 102.20M | — | 75.31M | — |
| Diluted shares | — | 102.20M | — | 75.31M | — |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | YoY |
|---|---|---|---|---|
| Cash & equivalents | $58.48M | $63.86M | $66.52M | -8.4% |
| Cash & short-term investments | $427.25M | $455.82M | $480.00M | -6.3% |
| Total current assets | $441.54M | $468.72M | $493.38M | -5.8% |
| Property, plant & equipment | $10.98M | $11.60M | $12.07M | -5.3% |
| Total assets | $456.33M | $482.56M | $507.65M | -5.4% |
| Total current liabilities | $34.01M | $29.75M | $30.48M | +14.3% |
| Total debt | $6.90M | $7.33M | $7.74M | -5.9% |
| Total liabilities | $707.38M | $708.29M | $709.91M | -0.1% |
| Retained earnings | -$269.13M | -$243.37M | -$220.70M | -10.6% |
| Shareholder equity | -$251.05M | -$225.73M | -$202.25M | -11.2% |
| Working capital | $407.53M | $438.96M | $462.89M | -7.2% |
| Net tangible assets | -$251.05M | -$225.73M | -$202.25M | -11.2% |
| Shares issued | 102.20M | 102.20M | — | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|
| Net income | -$25.76M | -$22.67M | -$18.09M | -$15.55M | -13.6% |
| Depreciation & amortisation | $735.00K | $720.00K | $626.00K | $514.00K | +2.1% |
| Stock-based compensation | $1.51M | $837.00K | $1.15M | $1.73M | +79.9% |
| Change in working capital | -$3.59M | -$1.36M | $330.53M | $1.64M | -164.5% |
| Operating cash flow | -$27.19M | -$22.68M | $313.44M | -$12.71M | -19.9% |
| Capital expenditure | -$367.00K | -$77.00K | -$992.00K | -$497.00K | -376.6% |
| Investing cash flow | $21.76M | $19.96M | -$263.17M | $13.94M | +9.0% |
| Financing cash flow | $6.00K | $2.00K | $83.00K | $0 | +200.0% |
| Free cash flow | -$27.56M | -$22.76M | $312.45M | -$13.20M | -21.1% |
| End cash position | $58.48M | $63.86M | $65.64M | $15.27M | -8.4% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $0 | — |
| Next year | — | — | $0 | — |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders41.78%
Held by institutions29.57%
Institutions holding4
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
—
—
SMA 20
—
—
SMA 50
—
—
SMA 100
—
—
SMA 200
—
—
EMA 12
—
—
EMA 26
—
—
EMA 50
—
—
RSI (14)
—
—
MACD (12,26,9)
—
Hist —
ATR (14)
—
—
Realised vol 30D
—
Annualised
Bollinger upper
—
20, 2σ
Bollinger lower
—
20, 2σ
50 / 200 cross
—
—
Trend bias
—
—
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
—
—
Correlation to SPY
—
—
Realised vol 30D
—
Annualised
Market vol 1Y
—
SPY, annualised
Max drawdown 1Y
-11.6%
Peak to trough
Max drawdown 5Y
-11.6%
Peak to trough
ATR 14
—
Average true range
Beta (reported)
—
5Y monthly, from filing
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
Headlines
ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares Granted in Its Initial Public Offering
GlobeNewswire · 6d ago
ADARx Pharmaceuticals (ADRX) Moved Higher, But What Is Drawing Attention?
Simply Wall St. · 9d ago
ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering
GlobeNewswire · 12d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.